青少年和年轻成人癌症幸存者的第二原发恶性肿瘤与生存
这项基于美国13个SEER登记处的回顾性队列研究纳入1992至2008年诊断、随访至2013年的15 954例儿童、125 750例青少年和年轻成人(AYA)及878 370例老年患者,比较第二原发恶性肿瘤(SPM)与相同癌症作为第一原发恶性肿瘤(PM)的5年相对生存。AYA发生SPM后的5年生存较同年龄PM低20.2%,多种SPM的生存显著更差。
要点
- AYA发生SPM后5年生存较同年龄PM低20.2%,儿童低33.1%,老年人低8.3%。
- AYA常见SPM中,继发非霍奇金淋巴瘤5年生存绝对差42%,继发乳腺癌19%,继发甲状腺癌15%,继发软组织肉瘤13%。
- AYA继发霍奇金淋巴瘤、软组织肉瘤、乳腺癌、急性髓系白血病、中枢神经系统肿瘤的生存较同癌种PM更差。
核心结论
- SPM对AYA生存的不利影响 substantial,可能部分解释AYA与其他年龄组相比生存改善相对不足。
- 特定SPM诊断对生存的影响可为年龄特异性预防、筛查、治疗和幸存者建议提供信息。
研究设计与样本
- 基于美国13个SEER登记区域的人群基础回顾性队列研究,纳入1992至2008年诊断、随访至2013年的患者。
- 共纳入15 954例儿童(<15岁)、125 750例AYA(15-39岁)和878 370例老年(≥40岁)患者,涵盖14种作为PM或SPM发生的癌症。
- 数据分析于2016年6月至2017年1月进行。
主要发现
- SPM后5年生存较同年龄PM:儿童低33.1%,AYA低20.2%,老年人低8.3%。
- AYA常见SPM的5年生存绝对差:继发非霍奇金淋巴瘤低42%,继发乳腺癌低19%,继发甲状腺癌低15%,继发软组织肉瘤低13%。
- 甲状腺癌、霍奇金淋巴瘤、非霍奇金淋巴瘤、急性髓系白血病、软组织肉瘤和中枢神经系统肿瘤中,SPM状态对生存的影响在年轻患者中显著差于老年患者。
- AYA继发霍奇金淋巴瘤风险比(95%CI)为3.5(1.7-7.1),软组织肉瘤为2.8(2.1-3.9),乳腺癌为2.1(1.8-2.4),急性髓系白血病为1.9(1.5-2.4),中枢神经系统肿瘤为1.8(1.2-2.8),均较同癌种PM的AYA生存更差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age. OBJECTIVE: To assess the survival impact of SPMs in adolescents and young adults (AYAs) (15-39 years) compared with that of pediatric (<15 years) and older adult (≥40 years) patients with the same SPMs. DESIGN, SETTING, AND PARTICIPANTS: This was a population-based, retrospective cohort study of patients with cancer in 13 Surveillance, Epidemiology and End Results regions in the United States diagnosed from 1992 to 2008 and followed through 2013. Data analysis was performed between June 2016 and January 2017. MAIN OUTCOMES AND MEASURES: Five-year relative survival was calculated overall and for each cancer occurring as a PM or SPM by age at diagnosis. The impact of SPM status on cancer-specific death was examined using multivariable Cox proportional hazards regression. RESULTS: A total of 15 954 pediatric, 125 750 AYAs, and 878 370 older adult patients diagnosed as having 14 cancers occurring as a PM or SPM were included. Overall, 5-year survival after an SPM was 33.1% lower for children, 20.2% lower for AYAs, and 8.3% lower for older adults compared with a PM at the same age. For the most common SPMs in AYAs, the absolute difference in 5-year survival was 42% lower for secondary non-Hodgkin lymphoma, 19% for secondary breast carcinoma, 15% for secondary thyroid carcinoma, and 13% for secondary soft-tissue sarcoma. Survival by SPM status was significantly worse in younger vs older patients for thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, soft-tissue sarcoma, and central nervous system cancer. Adolescents and young adults with secondary Hodgkin lymphoma (hazard ratio [95% CI], 3.5 [1.7-7.1]); soft-tissue sarcoma (2.8 [2.1-3.9]); breast carcinoma (2.1 [1.8-2.4]); acute myeloid leukemia (1.9 [1.5-2.4]); and central nervous system cancer (1.8 [1.2-2.8]) experienced worse survival compared with AYAs with the same PMs. CONCLUSION AND RELEVANCE: The adverse impact of SPMs on survival is substantial for AYAs and may partially explain the relative lack of survival improvement in AYAs compared with other age groups. The impact of a particular SPM diagnosis on survival may inform age-specific prevention, screening, treatment, and survivorship recommendations.
引用
- Keegan THM, Bleyer A, Rosenberg AS, et al. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. JAMA Oncol. 2017. PMID: 28426850. doi:10.1001/jamaoncol.2017.0465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。